Mycobacterium Avium Subspecies Paratuberculosis Infection and Biological Treatment of IBD
| Autor: | E Proietti, Maikel P. Peppelenbosch, Gwenny M. Fuhler |
|---|---|
| Přispěvatelé: | Gastroenterology & Hepatology |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Crohn’s disease Polymerase Chain Reaction Cohort Studies disease progression Crohn Disease Eccojc/1080 Animals Humans Medicine genetics AcademicSubjects/MED00260 Antigens Bacterial biology business.industry Editorials Gastroenterology Reproducibility of Results nflammatory bowel disease Original Articles General Medicine Middle Aged Inflammatory Bowel Diseases Eccojc/1020 biology.organism_classification Antibodies Bacterial Mycobacterium avium subspecies paratuberculosis Virology Eccojc/1000 Immunoglobulin A Biological Therapy Mycobacterium avium subsp. paratuberculosis Cross-Sectional Studies Immunoglobulin M Mycobacterium avium paratuberculosis isotype-specific testing Female business Genome-Wide Association Study |
| Zdroj: | Journal of Crohn's & colitis, 15(8), 1247-1249. Oxford University Press Journal of Crohn's & Colitis |
| ISSN: | 1873-9946 |
| DOI: | 10.1093/ecco-jcc/jjab027 |
| Popis: | Background The role of Mycobacterium avium paratuberculosis [MAP] in inflammatory bowel disease [IBD], especially Crohn’s disease [CD] is controversial due conflicting results and lack of reproducibility and standardised tests. The current study focuses on the role of MAP in disease progression and genetic susceptibility, as MAP is likely one of many factors involved in the complex pathogenesis of IBD, potentially affecting a subgroup depending on genetic susceptibility. Methods Serum from 812 patients was evaluated with seven immunoglobulin [Ig] isotype-specific serology tests assessing humoral response to three different MAP antigens. For each of these in total 21 tests, the intra-assay and inter-assay coefficients were used to evaluate test accuracy. Reliable assays were subsequently analysed in relation to disease characteristics and need for biologic therapy/surgery. Genome-wide genotyping was available for all participants. Genetic determinants of humoral response to MAP antigens were evaluated using genome-wide association analysis and polygenic risk scores [PRS]. Results High IgA or IgM response to MAP2609 was associated with increased use of biologic therapy in CD and ulcerative colitis [UC] [odds ratios 2.69; 95% confidence interval 1.44–5.01; and 2.60, 1.46–4.64, respectively]. No associations were seen for risk of surgery [p-values > 0.29]. We could not identify genetic determinants nor polygenic risk scores for MAP response with genome-wide significance. Conclusions Extensive assays for serological response to MAP were evaluated using stringent criteria for reliability. Increased IgA and IgM response to MAP antigens was seen in patients exposed to biologic therapy, but no genetic determinants underlying this humoral response were found. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |